Onychomycosis News and Research

RSS
Onychomycosis (also known as "Dermatophytic onychomycosis," "Ringworm of the nail," It is the most common disease of the nails and constitutes about a half of all nail abnormalities.
Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Overview of chlamydia trachomatis infections

Overview of chlamydia trachomatis infections

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Nestlé focuses on meeting world's increasing skin health needs

Nestlé focuses on meeting world's increasing skin health needs

Moberg announces positive results from phase ll study of MOB-015 for treatment of nail fungus

Moberg announces positive results from phase ll study of MOB-015 for treatment of nail fungus

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

LSO Medical, GME German Medical Engineering form strategic partnership

LSO Medical, GME German Medical Engineering form strategic partnership

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Valeant Pharmaceuticals receives Complete Response Letter from FDA for efinaconazole NDA

Valeant Pharmaceuticals receives Complete Response Letter from FDA for efinaconazole NDA

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Cynosure closes underwritten registered public offering of class A common stock

Cynosure closes underwritten registered public offering of class A common stock

Sprucing up treatment for fungal nail infection

Sprucing up treatment for fungal nail infection

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium